华球体育-华球(中国)公司

Beihai Biotech announced that its innovative cancer drug, BH009 (marketed as BEIZRAY), has received approval from the U.S. Food and Drug Administration (FDA)

2024-10-31
U.S. FDA Formally Accepts Beihai Biotech's New Drug Application for Innovative Oncology Drug BH009 (BEIZRAY™)

2024-01-04
Beihai Biotech Founder Dr. Sun Invited to Keynote 'Wisdom in China' Summit at Renmin University Business School

2023-12-26
Beihai Biotech Successfully Concludes Series C Funding, Expediting BH009 Commercialization and Advancing Clinical Trials for Innovative Drug Candidates

2023-12-19
Beihai Biotech Listed Among "Top 100 High-Growth Enterprises in the Greater Bay Area 2023"

2023-11-09
Innovation Recognized Again: Beihai Biotech Honored with GHP “Most Innovative Clinical-Stage Biopharmaceutical Company 2023”

2023-08-01
Beihai Biotech Secures “Drug Manufacturing Certificate”

2023-06-15
Landmark Clinical Research Findings of Beihai Biotech's BH009 Unveiled at ASCO 2023

2023-06-12

米兰.体育 (中国) 官方网站 | 乐竞体育·(LEJING SPORTS)官方网站 | 开云登陆入口 | 乐鱼网页版-乐鱼(中国) | 华球体育_华球(中国)公司 | 开云真人（中国）体育官方网站 | 星空体育·（StarSky Sports）官方网站 | 米兰手机版app | 乐动 |